Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone
KEYNOTE-042 (PDL1>20%), 2019
  NCT02220894
RCTmNSCLC - L1 - PDL1 positivepembrolizumabplatinium based chemotherapypreviously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 20% or greater413 / 405some concern
conclusif
  • demonstrated 23 % decrease in deaths (OS) (PE)
  • suggested 25 % decrease in deaths (OS) (extension)
KEYNOTE-042 (PDL1>1%), 2019
  NCT02220894
RCTmNSCLC - L1 - PDL1 positivepembrolizumabplatinium based chemotherapypreviously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 1% or greater637 / 637some concern
conclusif
  • demonstrated 19 % decrease in deaths (OS) (PE)
  • suggested 20 % decrease in deaths (OS) (extension)
KEYNOTE-042 (PDL1>50%), 2019
  NCT02220894
RCTmNSCLC - L1 - PDL1 positivepembrolizumabplatinium based chemotherapypreviously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 50% or greater299 / 300some concern
conclusif
  • demonstrated 31 % decrease in deaths (OS) (PE)
  • suggested 2 % decrease in deaths (OS) (extension)
  • suggested 19 % decrease in progression or deaths (PFS)
KEYNOTE-024 (PDL1>50%), 2016
  NCT02142738
RCTmNSCLC - L1 - PDL1 positivePembrolizumabICC platinum-based chemotherapies regimenspatients who had previously untreated advanced stage IV NSCLC with PD-L1 expression on at least 50% of tumor cells154 / 151some concern
conclusif
  • demonstrated 40 % decrease in deaths (OS) (PE)
  • demonstrated 50 % decrease in progression or deaths (PFS) (PE)
  • suggested 38 % decrease in deaths (OS) (extension)
  • suggested 50 % decrease in PFS (extension)

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus pemetrexed plus platin
pembrolizumab and pemetrexed plus platin
KEYNOTE-021, 2016
  NCT02039674
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)pembrolizumab with carboplatin plus pemetrexedcarboplatin plus pemetrexedpatients with stage IIIB/IV, chemotherapy-naive, nonsquamous non-small-cell lung cancer60 / 63some concern
conclusif
  • demonstrated 47 % decrease in progression or deaths (PFS) (PE)
  • suggested 46 % decrease in PFS (extension)
  • demonstrated 2.1-fold increase in objective responses (ORR) (PE)
versus placebo plus SoC
pembrolizumab plus SoC
KEYNOTE-189, 2018
  NCT02578680
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)pembrolizumab plus pemetrexed plus platineplacebo plus pemetrexed plus platineparticipants with advanced or metastatic nonsquamous non-small cell lung cancer who have not previously received systemic therapy for advanced disease410 / 206low
conclusif
  • demonstrated 51 % decrease in deaths (OS) (PE)
  • demonstrated 48 % decrease in progression or deaths (PFS) (PE)
  • suggested 44 % decrease in deaths (OS) (extension)
  • suggested 52 % decrease in PFS (extension)
  • more...

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus placebo plus SoC
pembrolizumab plus SoC
KEYNOTE-407, 2018
  NCT02775435
RCTsquamous - mNSCLC - L1 - all populationpembrolizumab plus platine and (nab)paclitaxelplacebo plus platine and (nab)paclitaxelpatients with confirmed stage IV squamous NSCLC who had received no previous systemic therapy for metastatic disease278 / 281low
conclusif
  • demonstrated 36 % decrease in deaths (OS) (PE)
  • demonstrated 44 % decrease in progression or deaths (PFS) (PE)

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
pembrolizumab (10mg/kg)
KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 10 mg/kgdocetaxelpatients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 50% of tumour cells151 / 152high
conclusif
  • demonstrated 50 % decrease in deaths (OS) (PE)
  • demonstrated 41 % decrease in progression or deaths (PFS) (PE)
  • suggested 45 % decrease in deaths (OS) (extension)
  • suggested 43 % decrease in PFS (extension)
KEYNOTE-010 (P:10 mg/kg), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 10 mg/kgdocetaxelpatients with previously treated (one line or more) non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells346 / 343high
conclusif
  • demonstrated 39 % decrease in deaths (OS) (PE)
  • suggested 21 % decrease in progression or deaths (PFS) (PE)
pembrolizumab (2mg/kg)
KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 2 mg/kgdocetaxelpatients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 50% of tumour cells139 / 152high
conclusif
  • demonstrated 46 % decrease in deaths (OS) (PE)
  • demonstrated 41 % decrease in progression or deaths (PFS) (PE)
KEYNOTE-010 (P: 2mg/kg), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 2 mg/kgdocetaxelpatients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells344 / 343high
conclusif
  • demonstrated 29 % decrease in deaths (OS) (PE)
  • inconclusive 12 % decrease in progression or deaths (PFS) (PE)